Testosterone synthesis

Disclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as marked. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Mercola and his community. Dr. Mercola encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content.

Testosterone postmenopausale alto e rischi metabolici
Nelle donne in postmenopausa, livelli elevati di testosterone aumentano il rischio di resistenza all'insulina, sindrome metabolica e patologie coronariche. Sono i risultati di un trial pubblicato su Journal of Clinical Endocrinology and Metabolism. L'indagine ha riguardato 344 donne di età media pari a 74,4 anni in cui è emerso che l'incremento del testosterone totale (p = 0,003) e libero (p = 0,02) determina un aumento graduale della resistenza all'insulina e, conseguentemente, una graduale diminuzione della sensibilità all'insulina (p< 0,001 e p = 0,002, rispettivamente). Livelli elevati di testosterone totale e libero sono, inoltre, risultati associati a obesità addominale, elevato glucosio a digiuno e alle due componenti della sindrome metabolica maggiormente legate alla resistenza all'insulina. Le donne con il maggiore contenuto di testosterone totale hanno mostrato un rischio di sindrome metabolica e patologie cardiovascolari molto più elevato rispetto a quelle con livelli inferiori (or= 3,15 e 2,95, rispettivamente). Le concentrazioni di testosterone libero non sono, invece, correlate né a sindrome metabolica né malattie cardiovascolari. "Trattandosi di uno studio osservazionale, non possiamo ancora stabilire se il testosterone può considerarsi un marker o mediatore di patologie cardiovascolari in donne anziane" ha commentato Anne R. Cappola, principale autore dello studio. (.)

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Testosterone synthesis

testosterone synthesis


testosterone synthesistestosterone synthesistestosterone synthesistestosterone synthesistestosterone synthesis